Erdafitinib's effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer

• Main Authors: Anne‐Gaëlle Dosne (Author), Elodie Valade (Author), Kim Stuyckens (Author), Peter De Porre (Author), Anjali Avadhani (Author), Anne O'Hagan (Author), Lilian Y. Li (Author), Daniele Ouellet (Author), Ruben Faelens (Author), Quentin Leirens (Author), Italo Poggesi (Author), Juan Jose Perez Ruixo (Author)
• Format: Book
• Published: Wiley, 2022-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract A population pharmacokinetic (PK)-pharmacodynamic (PD) model was developed using data from 345 patients with cancer. The population PK‐PD model evaluated the effect of erdafitinib total and free plasma concentrations on serum phosphate concentrations after once‐daily oral continuous (0.5-12...